{"status": "Succeeded", "recognitionResults": [{"page": 1, "clockwiseOrientation": 359.95, "width": 1700, "height": 2236, "unit": "pixel", "lines": [{"boundingBox": [208, 171, 791, 170, 792, 204, 209, 205], "text": "see this story from CNN for more details", "words": [{"boundingBox": [222, 172, 273, 172, 274, 206, 223, 205], "text": "see"}, {"boundingBox": [280, 172, 332, 172, 334, 206, 281, 206], "text": "this"}, {"boundingBox": [339, 172, 412, 173, 413, 206, 340, 206], "text": "story"}, {"boundingBox": [419, 173, 480, 173, 482, 206, 420, 206], "text": "from"}, {"boundingBox": [496, 173, 558, 173, 559, 206, 498, 206], "text": "CNN"}, {"boundingBox": [566, 172, 608, 172, 610, 206, 568, 206], "text": "for"}, {"boundingBox": [615, 172, 690, 172, 692, 206, 617, 206], "text": "more"}, {"boundingBox": [697, 172, 789, 171, 792, 205, 699, 206], "text": "details"}]}, {"boundingBox": [204, 302, 1133, 302, 1133, 335, 205, 336], "text": "3. Regulators may order Tressa off market after trial failure", "words": [{"boundingBox": [205, 303, 234, 303, 235, 335, 206, 335], "text": "3."}, {"boundingBox": [240, 303, 412, 304, 413, 336, 241, 335], "text": "Regulators"}, {"boundingBox": [419, 304, 487, 304, 488, 336, 419, 336], "text": "may"}, {"boundingBox": [496, 304, 583, 304, 583, 337, 496, 336], "text": "order"}, {"boundingBox": [589, 304, 691, 304, 691, 337, 589, 337], "text": "Tressa", "confidence": "Low"}, {"boundingBox": [697, 304, 741, 304, 740, 337, 697, 337], "text": "off"}, {"boundingBox": [747, 304, 863, 304, 863, 336, 747, 337], "text": "market"}, {"boundingBox": [869, 304, 948, 304, 948, 336, 869, 336], "text": "after"}, {"boundingBox": [954, 304, 1021, 303, 1020, 336, 954, 336], "text": "trial"}, {"boundingBox": [1027, 303, 1131, 302, 1130, 335, 1026, 336], "text": "failure"}]}, {"boundingBox": [199, 369, 1475, 368, 1475, 401, 200, 403], "text": "The FDA is considering removing AstraZeneca's Tressa from the market after a trial showed", "words": [{"boundingBox": [204, 370, 256, 371, 257, 401, 205, 400], "text": "The"}, {"boundingBox": [262, 371, 320, 371, 321, 401, 263, 401], "text": "FDA"}, {"boundingBox": [326, 371, 352, 372, 353, 402, 327, 401], "text": "is"}, {"boundingBox": [358, 372, 521, 373, 522, 402, 359, 402], "text": "considering"}, {"boundingBox": [527, 373, 661, 374, 662, 403, 528, 402], "text": "removing"}, {"boundingBox": [667, 374, 867, 374, 867, 403, 668, 403], "text": "AstraZeneca's"}, {"boundingBox": [873, 374, 960, 374, 961, 403, 873, 403], "text": "Tressa", "confidence": "Low"}, {"boundingBox": [966, 374, 1026, 373, 1027, 402, 967, 403], "text": "from"}, {"boundingBox": [1042, 373, 1090, 373, 1090, 402, 1043, 402], "text": "the"}, {"boundingBox": [1096, 373, 1200, 372, 1200, 401, 1096, 402], "text": "market"}, {"boundingBox": [1206, 372, 1276, 371, 1276, 401, 1206, 401], "text": "after"}, {"boundingBox": [1282, 371, 1302, 371, 1302, 400, 1282, 401], "text": "a"}, {"boundingBox": [1308, 371, 1366, 370, 1365, 400, 1308, 400], "text": "trial"}, {"boundingBox": [1372, 370, 1473, 368, 1473, 398, 1371, 400], "text": "showed"}]}, {"boundingBox": [198, 404, 1449, 402, 1450, 436, 199, 437], "text": "that it was ineffective in prolonging the lives of lung cancer patients. AstraZeneca says it", "words": [{"boundingBox": [201, 404, 260, 405, 260, 435, 201, 434], "text": "that"}, {"boundingBox": [265, 405, 287, 405, 287, 435, 266, 435], "text": "it"}, {"boundingBox": [293, 405, 352, 405, 352, 436, 293, 435], "text": "was"}, {"boundingBox": [358, 405, 505, 405, 505, 436, 358, 436], "text": "ineffective"}, {"boundingBox": [511, 405, 538, 405, 539, 437, 511, 436], "text": "in"}, {"boundingBox": [546, 406, 695, 406, 696, 437, 547, 437], "text": "prolonging"}, {"boundingBox": [703, 406, 752, 406, 753, 437, 704, 437], "text": "the"}, {"boundingBox": [758, 406, 823, 406, 824, 437, 759, 437], "text": "lives"}, {"boundingBox": [829, 406, 858, 406, 859, 437, 829, 437], "text": "of"}, {"boundingBox": [864, 406, 929, 406, 930, 437, 865, 437], "text": "lung"}, {"boundingBox": [937, 406, 1031, 405, 1032, 436, 938, 437], "text": "cancer"}, {"boundingBox": [1037, 405, 1161, 405, 1162, 435, 1038, 436], "text": "patients."}, {"boundingBox": [1167, 405, 1345, 404, 1346, 434, 1167, 435], "text": "AstraZeneca"}, {"boundingBox": [1351, 404, 1414, 404, 1415, 433, 1352, 434], "text": "says"}, {"boundingBox": [1420, 403, 1447, 403, 1448, 433, 1421, 433], "text": "it"}]}, {"boundingBox": [199, 436, 1482, 434, 1482, 465, 200, 468], "text": "will not pull the drug on its own but has decided to stop promoting it. Iressa was one of the", "words": [{"boundingBox": [200, 437, 249, 437, 251, 467, 202, 466], "text": "will"}, {"boundingBox": [255, 437, 304, 437, 305, 467, 257, 467], "text": "not"}, {"boundingBox": [310, 437, 365, 437, 366, 467, 311, 467], "text": "pull"}, {"boundingBox": [371, 437, 420, 437, 421, 467, 372, 467], "text": "the"}, {"boundingBox": [425, 437, 492, 437, 493, 467, 427, 467], "text": "drug"}, {"boundingBox": [500, 437, 535, 437, 536, 468, 501, 467], "text": "on"}, {"boundingBox": [543, 437, 580, 437, 581, 468, 544, 468], "text": "its"}, {"boundingBox": [586, 437, 646, 437, 647, 468, 587, 468], "text": "own"}, {"boundingBox": [652, 437, 701, 437, 702, 468, 653, 468], "text": "but"}, {"boundingBox": [707, 437, 764, 436, 764, 468, 708, 468], "text": "has"}, {"boundingBox": [772, 436, 877, 436, 878, 468, 772, 468], "text": "decided"}, {"boundingBox": [883, 436, 915, 436, 915, 468, 884, 468], "text": "to"}, {"boundingBox": [922, 436, 983, 436, 983, 467, 923, 468], "text": "stop"}, {"boundingBox": [991, 436, 1136, 436, 1136, 467, 991, 467], "text": "promoting"}, {"boundingBox": [1142, 436, 1175, 436, 1175, 467, 1142, 467], "text": "it."}, {"boundingBox": [1181, 436, 1271, 435, 1270, 466, 1181, 467], "text": "Iressa"}, {"boundingBox": [1277, 435, 1335, 435, 1335, 466, 1276, 466], "text": "was"}, {"boundingBox": [1341, 435, 1394, 435, 1394, 466, 1341, 466], "text": "one"}, {"boundingBox": [1400, 435, 1429, 435, 1429, 465, 1399, 466], "text": "of"}, {"boundingBox": [1435, 435, 1482, 434, 1481, 465, 1435, 465], "text": "the"}]}, {"boundingBox": [201, 470, 1483, 467, 1483, 499, 202, 502], "text": "first in a new category of cancer drugs that promised to interfere with the development of a", "words": [{"boundingBox": [202, 471, 259, 471, 259, 501, 202, 501], "text": "first"}, {"boundingBox": [265, 471, 292, 471, 292, 501, 265, 501], "text": "in"}, {"boundingBox": [300, 471, 319, 471, 319, 501, 300, 501], "text": "a"}, {"boundingBox": [327, 471, 380, 471, 379, 501, 327, 501], "text": "new"}, {"boundingBox": [393, 471, 518, 471, 517, 501, 393, 501], "text": "category"}, {"boundingBox": [524, 471, 555, 471, 554, 501, 523, 501], "text": "of"}, {"boundingBox": [561, 471, 656, 471, 655, 501, 560, 501], "text": "cancer"}, {"boundingBox": [662, 471, 742, 471, 741, 501, 661, 501], "text": "drugs"}, {"boundingBox": [748, 471, 808, 471, 807, 501, 747, 501], "text": "that"}, {"boundingBox": [814, 471, 948, 470, 947, 501, 813, 501], "text": "promised"}, {"boundingBox": [954, 470, 985, 470, 984, 501, 953, 501], "text": "to"}, {"boundingBox": [991, 470, 1114, 470, 1112, 500, 990, 501], "text": "interfere"}, {"boundingBox": [1119, 470, 1180, 469, 1179, 500, 1118, 500], "text": "with"}, {"boundingBox": [1188, 469, 1236, 469, 1235, 500, 1186, 500], "text": "the"}, {"boundingBox": [1244, 469, 1425, 467, 1424, 499, 1243, 500], "text": "development"}, {"boundingBox": [1431, 467, 1462, 467, 1461, 499, 1429, 499], "text": "of"}, {"boundingBox": [1468, 467, 1484, 467, 1482, 498, 1466, 499], "text": "a"}]}, {"boundingBox": [197, 501, 1409, 499, 1410, 533, 198, 535], "text": "tumor without the harsh side effects associated with chemotherapy. In trials, the drug", "words": [{"boundingBox": [203, 503, 287, 503, 286, 534, 202, 534], "text": "tumor"}, {"boundingBox": [293, 503, 402, 502, 401, 534, 292, 534], "text": "without"}, {"boundingBox": [408, 502, 458, 502, 458, 534, 407, 534], "text": "the"}, {"boundingBox": [464, 502, 545, 502, 544, 535, 464, 534], "text": "harsh"}, {"boundingBox": [553, 502, 613, 502, 612, 535, 552, 535], "text": "side"}, {"boundingBox": [619, 502, 714, 501, 713, 535, 619, 535], "text": "effects"}, {"boundingBox": [720, 501, 868, 501, 868, 535, 719, 535], "text": "associated"}, {"boundingBox": [875, 501, 937, 501, 937, 535, 874, 535], "text": "with"}, {"boundingBox": [943, 501, 1154, 500, 1154, 534, 943, 535], "text": "chemotherapy."}, {"boundingBox": [1160, 500, 1192, 500, 1192, 534, 1160, 534], "text": "In"}, {"boundingBox": [1200, 500, 1283, 500, 1283, 533, 1200, 534], "text": "trials,"}, {"boundingBox": [1289, 500, 1337, 500, 1337, 533, 1289, 533], "text": "the"}, {"boundingBox": [1345, 500, 1410, 500, 1409, 533, 1345, 533], "text": "drug"}]}, {"boundingBox": [197, 533, 1475, 531, 1476, 564, 198, 565], "text": "shrank tumors in 10 percent of patients who had failed to respond to other treatments. But", "words": [{"boundingBox": [204, 533, 298, 533, 297, 566, 203, 566], "text": "shrank"}, {"boundingBox": [304, 533, 405, 534, 404, 566, 303, 566], "text": "tumors"}, {"boundingBox": [411, 534, 443, 534, 443, 566, 410, 566], "text": "in"}, {"boundingBox": [452, 534, 486, 534, 485, 566, 451, 566], "text": "10"}, {"boundingBox": [492, 534, 604, 534, 603, 566, 492, 566], "text": "percent"}, {"boundingBox": [610, 534, 638, 534, 637, 565, 610, 566], "text": "of"}, {"boundingBox": [644, 534, 758, 534, 757, 565, 644, 565], "text": "patients"}, {"boundingBox": [764, 534, 824, 534, 824, 565, 764, 565], "text": "who"}, {"boundingBox": [830, 534, 886, 534, 886, 565, 830, 565], "text": "had"}, {"boundingBox": [892, 534, 972, 534, 972, 565, 892, 565], "text": "failed"}, {"boundingBox": [978, 534, 1010, 534, 1010, 565, 978, 565], "text": "to"}, {"boundingBox": [1016, 534, 1130, 533, 1130, 565, 1017, 565], "text": "respond"}, {"boundingBox": [1136, 533, 1166, 533, 1167, 564, 1137, 565], "text": "to"}, {"boundingBox": [1173, 533, 1250, 533, 1250, 564, 1173, 564], "text": "other"}, {"boundingBox": [1256, 533, 1423, 532, 1424, 564, 1257, 564], "text": "treatments."}, {"boundingBox": [1429, 532, 1474, 532, 1475, 564, 1430, 564], "text": "But"}]}, {"boundingBox": [196, 567, 1480, 564, 1481, 599, 197, 602], "text": "when the FDA gave its approval to Iressa, it required a follow-up study to demonstrate that", "words": [{"boundingBox": [201, 569, 277, 569, 278, 600, 203, 600], "text": "when"}, {"boundingBox": [284, 570, 334, 570, 335, 600, 286, 600], "text": "the"}, {"boundingBox": [340, 570, 397, 570, 399, 601, 341, 600], "text": "FDA"}, {"boundingBox": [405, 570, 477, 570, 478, 601, 407, 601], "text": "gave"}, {"boundingBox": [483, 570, 520, 570, 521, 601, 484, 601], "text": "its"}, {"boundingBox": [526, 570, 649, 570, 650, 601, 527, 601], "text": "approval"}, {"boundingBox": [655, 570, 686, 570, 688, 601, 656, 601], "text": "to"}, {"boundingBox": [692, 570, 789, 569, 791, 601, 694, 601], "text": "Iressa,"}, {"boundingBox": [795, 569, 819, 569, 820, 601, 797, 601], "text": "it"}, {"boundingBox": [825, 569, 946, 569, 947, 601, 826, 601], "text": "required"}, {"boundingBox": [954, 569, 972, 569, 973, 601, 955, 601], "text": "a"}, {"boundingBox": [978, 569, 1110, 568, 1111, 600, 979, 601], "text": "follow-up"}, {"boundingBox": [1116, 568, 1197, 567, 1198, 600, 1117, 600], "text": "study"}, {"boundingBox": [1203, 567, 1233, 567, 1234, 600, 1204, 600], "text": "to"}, {"boundingBox": [1243, 567, 1419, 566, 1420, 598, 1244, 600], "text": "demonstrate"}, {"boundingBox": [1425, 566, 1481, 565, 1481, 598, 1426, 598], "text": "that"}]}, {"boundingBox": [200, 599, 1422, 598, 1423, 632, 201, 633], "text": "the drug prolonged patients' lives. That led to the results announced late last week and", "words": [{"boundingBox": [201, 601, 251, 601, 252, 633, 202, 633], "text": "the"}, {"boundingBox": [257, 601, 322, 601, 323, 633, 258, 633], "text": "drug"}, {"boundingBox": [329, 601, 471, 601, 472, 633, 329, 633], "text": "prolonged"}, {"boundingBox": [477, 601, 601, 601, 601, 634, 478, 634], "text": "patients'"}, {"boundingBox": [607, 601, 687, 601, 687, 634, 608, 634], "text": "lives."}, {"boundingBox": [693, 601, 754, 601, 754, 634, 694, 634], "text": "That"}, {"boundingBox": [760, 601, 806, 601, 807, 634, 761, 634], "text": "led"}, {"boundingBox": [813, 601, 844, 601, 844, 634, 813, 634], "text": "to"}, {"boundingBox": [850, 601, 898, 601, 899, 634, 851, 634], "text": "the"}, {"boundingBox": [905, 601, 1003, 601, 1003, 634, 905, 634], "text": "results"}, {"boundingBox": [1009, 601, 1162, 600, 1163, 633, 1010, 634], "text": "announced"}, {"boundingBox": [1169, 600, 1223, 600, 1223, 633, 1169, 633], "text": "late"}, {"boundingBox": [1229, 600, 1284, 600, 1284, 633, 1230, 633], "text": "last"}, {"boundingBox": [1290, 600, 1363, 599, 1364, 633, 1290, 633], "text": "week"}, {"boundingBox": [1370, 599, 1422, 599, 1422, 633, 1370, 633], "text": "and"}]}, {"boundingBox": [199, 633, 711, 634, 710, 666, 198, 664], "text": "leaves Iressa with a doubtful future.", "words": [{"boundingBox": [201, 634, 292, 634, 293, 663, 202, 665], "text": "leaves"}, {"boundingBox": [298, 634, 386, 634, 387, 662, 299, 663], "text": "Iressa"}, {"boundingBox": [392, 634, 454, 634, 455, 662, 393, 662], "text": "with"}, {"boundingBox": [462, 634, 483, 634, 484, 662, 463, 662], "text": "a"}, {"boundingBox": [491, 634, 606, 635, 607, 664, 492, 662], "text": "doubtful"}, {"boundingBox": [612, 635, 709, 635, 710, 666, 613, 664], "text": "future."}]}, {"boundingBox": [202, 695, 1169, 697, 1168, 733, 201, 731], "text": "see this story from The New York Times for more details (reg. req.)", "words": [{"boundingBox": [225, 697, 273, 697, 272, 730, 224, 730], "text": "see", "confidence": "Low"}, {"boundingBox": [280, 697, 334, 697, 333, 730, 278, 730], "text": "this"}, {"boundingBox": [341, 697, 413, 698, 412, 730, 340, 730], "text": "story"}, {"boundingBox": [420, 698, 481, 698, 480, 730, 418, 730], "text": "from"}, {"boundingBox": [498, 698, 549, 698, 547, 730, 497, 730], "text": "The"}, {"boundingBox": [555, 698, 617, 698, 615, 730, 554, 730], "text": "New"}, {"boundingBox": [627, 698, 693, 698, 692, 730, 626, 730], "text": "York"}, {"boundingBox": [700, 698, 783, 698, 781, 730, 698, 730], "text": "Times"}, {"boundingBox": [789, 698, 831, 697, 829, 731, 788, 730], "text": "for"}, {"boundingBox": [837, 697, 916, 697, 915, 731, 836, 731], "text": "more"}, {"boundingBox": [925, 697, 1014, 697, 1013, 732, 924, 731], "text": "details"}, {"boundingBox": [1021, 697, 1091, 697, 1090, 733, 1020, 732], "text": "(reg."}, {"boundingBox": [1098, 697, 1168, 697, 1166, 733, 1096, 733], "text": "req.)"}]}, {"boundingBox": [206, 828, 1214, 827, 1215, 862, 207, 863], "text": "4. Pharmos shares in meltdown after dexanabinol fails Phase III", "words": [{"boundingBox": [208, 829, 236, 829, 235, 860, 207, 860], "text": "4."}, {"boundingBox": [242, 829, 381, 831, 380, 862, 241, 860], "text": "Pharmos", "confidence": "Low"}, {"boundingBox": [387, 831, 493, 831, 493, 863, 386, 862], "text": "shares"}, {"boundingBox": [499, 831, 529, 831, 529, 863, 499, 863], "text": "in"}, {"boundingBox": [537, 832, 694, 832, 695, 864, 537, 863], "text": "meltdown"}, {"boundingBox": [702, 832, 781, 832, 782, 864, 703, 864], "text": "after"}, {"boundingBox": [788, 832, 981, 831, 983, 862, 789, 864], "text": "dexanabinol"}, {"boundingBox": [987, 831, 1054, 830, 1056, 862, 989, 862], "text": "fails"}, {"boundingBox": [1060, 830, 1156, 829, 1158, 861, 1062, 862], "text": "Phase"}, {"boundingBox": [1164, 829, 1211, 828, 1213, 860, 1166, 861], "text": "III"}]}, {"boundingBox": [204, 893, 1340, 894, 1339, 927, 203, 927], "text": "Shares of Israel's Pharmos melted away in pre-market trading after the company", "words": [{"boundingBox": [204, 894, 301, 894, 301, 927, 204, 927], "text": "Shares"}, {"boundingBox": [307, 894, 335, 894, 335, 927, 307, 927], "text": "of"}, {"boundingBox": [341, 894, 447, 894, 447, 928, 342, 927], "text": "Israel's"}, {"boundingBox": [453, 894, 577, 894, 578, 928, 453, 928], "text": "Pharmos"}, {"boundingBox": [584, 894, 683, 895, 683, 928, 584, 928], "text": "melted"}, {"boundingBox": [689, 895, 762, 895, 763, 928, 690, 928], "text": "away"}, {"boundingBox": [768, 895, 798, 895, 799, 928, 769, 928], "text": "in"}, {"boundingBox": [805, 895, 966, 895, 967, 927, 806, 928], "text": "pre-market"}, {"boundingBox": [972, 895, 1075, 895, 1076, 927, 973, 927], "text": "trading"}, {"boundingBox": [1082, 895, 1148, 895, 1149, 927, 1083, 927], "text": "after"}, {"boundingBox": [1154, 895, 1204, 895, 1205, 927, 1156, 927], "text": "the"}, {"boundingBox": [1210, 895, 1337, 895, 1338, 926, 1211, 927], "text": "company"}]}, {"boundingBox": [198, 930, 1366, 929, 1367, 961, 199, 962], "text": "announced that its lead drug candidate flunked a late-stage trial for treating severe", "words": [{"boundingBox": [203, 931, 355, 931, 356, 960, 203, 959], "text": "announced"}, {"boundingBox": [362, 931, 421, 931, 422, 961, 363, 960], "text": "that"}, {"boundingBox": [427, 931, 464, 931, 465, 961, 428, 961], "text": "its"}, {"boundingBox": [470, 931, 531, 931, 532, 962, 471, 961], "text": "lead"}, {"boundingBox": [540, 931, 604, 931, 605, 962, 541, 962], "text": "drug"}, {"boundingBox": [613, 931, 749, 931, 751, 962, 614, 962], "text": "candidate"}, {"boundingBox": [756, 931, 860, 931, 862, 962, 758, 962], "text": "flunked"}, {"boundingBox": [869, 931, 887, 931, 889, 962, 871, 962], "text": "a"}, {"boundingBox": [894, 931, 1038, 931, 1040, 961, 896, 962], "text": "late-stage"}, {"boundingBox": [1045, 931, 1104, 930, 1106, 961, 1047, 961], "text": "trial"}, {"boundingBox": [1109, 930, 1150, 930, 1153, 961, 1111, 961], "text": "for"}, {"boundingBox": [1156, 930, 1267, 930, 1269, 959, 1158, 961], "text": "treating"}, {"boundingBox": [1276, 930, 1364, 930, 1366, 958, 1278, 959], "text": "severe"}]}, {"boundingBox": [199, 961, 1411, 959, 1412, 994, 200, 996], "text": "traumatic brain injury. Researchers said that patients taking dexanabinol, which some", "words": [{"boundingBox": [202, 963, 339, 963, 340, 995, 203, 995], "text": "traumatic"}, {"boundingBox": [345, 963, 418, 963, 418, 995, 346, 995], "text": "brain"}, {"boundingBox": [424, 963, 519, 963, 520, 996, 425, 995], "text": "injury."}, {"boundingBox": [525, 963, 699, 963, 700, 996, 526, 996], "text": "Researchers"}, {"boundingBox": [705, 963, 763, 963, 764, 996, 706, 996], "text": "said"}, {"boundingBox": [769, 963, 829, 963, 831, 996, 771, 996], "text": "that"}, {"boundingBox": [836, 963, 951, 962, 953, 995, 837, 996], "text": "patients"}, {"boundingBox": [958, 962, 1049, 962, 1050, 995, 959, 995], "text": "taking"}, {"boundingBox": [1059, 962, 1235, 961, 1237, 994, 1061, 995], "text": "dexanabinol,"}, {"boundingBox": [1241, 961, 1324, 960, 1326, 994, 1243, 994], "text": "which"}, {"boundingBox": [1330, 960, 1409, 960, 1411, 993, 1332, 994], "text": "some"}]}, {"boundingBox": [201, 993, 1314, 994, 1313, 1024, 200, 1023], "text": "analysts believed had blockbuster potential, did not demonstrate any significant", "words": [{"boundingBox": [203, 995, 319, 995, 320, 1025, 204, 1024], "text": "analysts"}, {"boundingBox": [325, 995, 443, 994, 444, 1025, 326, 1025], "text": "believed"}, {"boundingBox": [449, 994, 505, 994, 506, 1025, 450, 1025], "text": "had"}, {"boundingBox": [513, 994, 676, 994, 676, 1025, 514, 1025], "text": "blockbuster"}, {"boundingBox": [682, 994, 825, 994, 825, 1025, 682, 1025], "text": "potential,"}, {"boundingBox": [831, 994, 869, 994, 870, 1025, 831, 1025], "text": "did"}, {"boundingBox": [875, 994, 929, 994, 929, 1025, 875, 1025], "text": "not"}, {"boundingBox": [937, 994, 1112, 995, 1111, 1025, 937, 1025], "text": "demonstrate"}, {"boundingBox": [1117, 995, 1172, 995, 1171, 1024, 1117, 1025], "text": "any"}, {"boundingBox": [1177, 995, 1313, 995, 1312, 1024, 1177, 1024], "text": "significant"}]}, {"boundingBox": [196, 1029, 1424, 1027, 1425, 1060, 197, 1062], "text": "improvement. Pharmos shares lost 77 percent of their value on the news. Pharmos has", "words": [{"boundingBox": [201, 1030, 400, 1030, 401, 1061, 202, 1060], "text": "improvement.", "confidence": "Low"}, {"boundingBox": [406, 1030, 531, 1030, 532, 1061, 407, 1061], "text": "Pharmos"}, {"boundingBox": [537, 1030, 631, 1030, 633, 1062, 538, 1061], "text": "shares"}, {"boundingBox": [637, 1029, 693, 1029, 694, 1062, 638, 1062], "text": "lost"}, {"boundingBox": [699, 1029, 737, 1029, 739, 1062, 700, 1062], "text": "77"}, {"boundingBox": [743, 1029, 853, 1029, 855, 1062, 745, 1062], "text": "percent"}, {"boundingBox": [859, 1029, 888, 1029, 889, 1061, 860, 1062], "text": "of"}, {"boundingBox": [894, 1029, 963, 1029, 964, 1061, 895, 1061], "text": "their"}, {"boundingBox": [969, 1029, 1046, 1029, 1047, 1061, 970, 1061], "text": "value"}, {"boundingBox": [1054, 1029, 1088, 1028, 1090, 1061, 1055, 1061], "text": "on"}, {"boundingBox": [1096, 1028, 1144, 1028, 1146, 1060, 1098, 1061], "text": "the"}, {"boundingBox": [1150, 1028, 1235, 1028, 1237, 1059, 1152, 1060], "text": "news."}, {"boundingBox": [1241, 1028, 1364, 1028, 1366, 1058, 1242, 1059], "text": "Pharmos"}, {"boundingBox": [1370, 1028, 1424, 1028, 1426, 1058, 1372, 1058], "text": "has"}]}, {"boundingBox": [202, 1060, 1462, 1058, 1463, 1093, 203, 1095], "text": "been developing compounds developed from cannabis for treating central nervous system", "words": [{"boundingBox": [205, 1062, 274, 1062, 272, 1094, 203, 1094], "text": "been"}, {"boundingBox": [284, 1062, 433, 1062, 432, 1094, 282, 1094], "text": "developing"}, {"boundingBox": [439, 1062, 607, 1061, 606, 1095, 438, 1094], "text": "compounds"}, {"boundingBox": [614, 1061, 755, 1061, 754, 1095, 612, 1095], "text": "developed"}, {"boundingBox": [761, 1061, 819, 1061, 818, 1095, 760, 1095], "text": "from"}, {"boundingBox": [835, 1061, 962, 1061, 961, 1095, 835, 1095], "text": "cannabis"}, {"boundingBox": [968, 1061, 1010, 1060, 1009, 1095, 967, 1095], "text": "for"}, {"boundingBox": [1016, 1060, 1128, 1060, 1127, 1094, 1015, 1095], "text": "treating"}, {"boundingBox": [1134, 1060, 1234, 1060, 1233, 1094, 1133, 1094], "text": "central"}, {"boundingBox": [1240, 1060, 1354, 1059, 1354, 1093, 1239, 1094], "text": "nervous"}, {"boundingBox": [1360, 1059, 1451, 1059, 1451, 1093, 1360, 1093], "text": "system"}]}, {"boundingBox": [199, 1093, 1408, 1092, 1409, 1124, 200, 1125], "text": "disorders. \"We are very disappointed and frankly somewhat perplexed that we did not", "words": [{"boundingBox": [208, 1094, 341, 1094, 339, 1126, 206, 1126], "text": "disorders."}, {"boundingBox": [347, 1094, 412, 1093, 410, 1126, 345, 1126], "text": "\"We"}, {"boundingBox": [418, 1093, 463, 1093, 462, 1126, 416, 1126], "text": "are"}, {"boundingBox": [470, 1093, 536, 1093, 535, 1126, 468, 1126], "text": "very"}, {"boundingBox": [545, 1093, 721, 1093, 721, 1126, 543, 1126], "text": "disappointed"}, {"boundingBox": [728, 1093, 784, 1093, 783, 1126, 727, 1126], "text": "and"}, {"boundingBox": [790, 1093, 890, 1093, 889, 1125, 789, 1126], "text": "frankly"}, {"boundingBox": [896, 1093, 1042, 1093, 1042, 1125, 896, 1125], "text": "somewhat"}, {"boundingBox": [1048, 1093, 1185, 1093, 1185, 1125, 1048, 1125], "text": "perplexed"}, {"boundingBox": [1191, 1093, 1252, 1093, 1252, 1124, 1192, 1124], "text": "that"}, {"boundingBox": [1258, 1093, 1302, 1093, 1302, 1124, 1258, 1124], "text": "we"}, {"boundingBox": [1312, 1093, 1351, 1094, 1352, 1124, 1312, 1124], "text": "did"}, {"boundingBox": [1358, 1094, 1408, 1094, 1408, 1123, 1358, 1124], "text": "not"}]}, {"boundingBox": [196, 1126, 1499, 1122, 1500, 1157, 197, 1161], "text": "observe any neuroprotective effect of dexanabinol in TBI,\" said Pharmos CEO Haim Aviv. \"In", "words": [{"boundingBox": [201, 1130, 314, 1130, 314, 1159, 202, 1159], "text": "observe"}, {"boundingBox": [321, 1130, 374, 1129, 374, 1159, 322, 1159], "text": "any"}, {"boundingBox": [381, 1129, 604, 1128, 605, 1159, 382, 1159], "text": "neuroprotective"}, {"boundingBox": [611, 1128, 692, 1128, 693, 1159, 612, 1159], "text": "effect"}, {"boundingBox": [698, 1128, 731, 1128, 732, 1159, 699, 1159], "text": "of"}, {"boundingBox": [737, 1128, 905, 1127, 907, 1159, 738, 1159], "text": "dexanabinol"}, {"boundingBox": [911, 1127, 939, 1127, 940, 1159, 912, 1159], "text": "in"}, {"boundingBox": [950, 1127, 1022, 1126, 1023, 1159, 952, 1159], "text": "TBI,\""}, {"boundingBox": [1027, 1126, 1085, 1126, 1087, 1159, 1029, 1159], "text": "said"}, {"boundingBox": [1091, 1126, 1216, 1125, 1218, 1158, 1092, 1159], "text": "Pharmos"}, {"boundingBox": [1222, 1125, 1278, 1125, 1280, 1158, 1224, 1158], "text": "CEO"}, {"boundingBox": [1289, 1125, 1353, 1124, 1355, 1158, 1291, 1158], "text": "Haim"}, {"boundingBox": [1370, 1124, 1443, 1124, 1445, 1158, 1372, 1158], "text": "Aviv."}, {"boundingBox": [1449, 1124, 1492, 1123, 1494, 1158, 1451, 1158], "text": "\"In"}]}, {"boundingBox": [200, 1158, 1426, 1157, 1426, 1191, 201, 1192], "text": "the next few weeks, we will carefully analyze the results of this trial before making final", "words": [{"boundingBox": [203, 1159, 250, 1159, 250, 1191, 203, 1191], "text": "the"}, {"boundingBox": [256, 1159, 320, 1159, 321, 1192, 257, 1191], "text": "next"}, {"boundingBox": [326, 1159, 376, 1159, 376, 1192, 327, 1192], "text": "few"}, {"boundingBox": [384, 1159, 484, 1159, 485, 1192, 385, 1192], "text": "weeks,"}, {"boundingBox": [491, 1159, 536, 1159, 536, 1192, 491, 1192], "text": "we"}, {"boundingBox": [542, 1159, 591, 1159, 591, 1192, 542, 1192], "text": "will"}, {"boundingBox": [597, 1159, 719, 1159, 719, 1192, 598, 1192], "text": "carefully"}, {"boundingBox": [725, 1159, 832, 1159, 832, 1192, 726, 1192], "text": "analyze"}, {"boundingBox": [839, 1159, 888, 1159, 888, 1192, 839, 1192], "text": "the"}, {"boundingBox": [894, 1159, 992, 1159, 992, 1192, 894, 1192], "text": "results"}, {"boundingBox": [999, 1159, 1026, 1159, 1026, 1192, 998, 1192], "text": "of"}, {"boundingBox": [1033, 1159, 1086, 1158, 1086, 1192, 1033, 1192], "text": "this"}, {"boundingBox": [1092, 1158, 1150, 1158, 1150, 1192, 1092, 1192], "text": "trial"}, {"boundingBox": [1156, 1158, 1248, 1158, 1248, 1192, 1156, 1192], "text": "before"}, {"boundingBox": [1255, 1158, 1359, 1157, 1359, 1191, 1254, 1192], "text": "making"}, {"boundingBox": [1366, 1157, 1425, 1157, 1425, 1191, 1365, 1191], "text": "final"}]}, {"boundingBox": [197, 1192, 1346, 1191, 1347, 1223, 198, 1224], "text": "decisions about our future plans, but it is unlikely that we will continue to develop", "words": [{"boundingBox": [208, 1194, 333, 1193, 333, 1223, 208, 1222], "text": "decisions"}, {"boundingBox": [339, 1193, 421, 1193, 421, 1224, 338, 1223], "text": "about"}, {"boundingBox": [426, 1193, 477, 1193, 477, 1224, 426, 1224], "text": "our"}, {"boundingBox": [482, 1193, 570, 1193, 570, 1224, 482, 1224], "text": "future"}, {"boundingBox": [578, 1193, 665, 1192, 665, 1225, 577, 1224], "text": "plans,"}, {"boundingBox": [671, 1192, 720, 1192, 719, 1225, 671, 1225], "text": "but"}, {"boundingBox": [725, 1192, 748, 1192, 747, 1225, 725, 1225], "text": "it"}, {"boundingBox": [753, 1192, 779, 1192, 779, 1225, 753, 1225], "text": "is"}, {"boundingBox": [785, 1192, 897, 1192, 897, 1225, 785, 1225], "text": "unlikely"}, {"boundingBox": [903, 1192, 964, 1192, 964, 1225, 902, 1225], "text": "that"}, {"boundingBox": [970, 1192, 1011, 1192, 1010, 1225, 969, 1225], "text": "we"}, {"boundingBox": [1018, 1192, 1067, 1192, 1066, 1225, 1018, 1225], "text": "will"}, {"boundingBox": [1073, 1192, 1194, 1192, 1193, 1224, 1072, 1225], "text": "continue"}, {"boundingBox": [1201, 1192, 1231, 1192, 1231, 1224, 1201, 1224], "text": "to"}, {"boundingBox": [1241, 1192, 1347, 1192, 1346, 1223, 1240, 1224], "text": "develop"}]}, {"boundingBox": [199, 1222, 498, 1223, 497, 1256, 198, 1255], "text": "dexanabinol for TBI.\"", "words": [{"boundingBox": [209, 1224, 374, 1227, 374, 1257, 209, 1254], "text": "dexanabinol"}, {"boundingBox": [380, 1227, 425, 1226, 425, 1256, 380, 1257], "text": "for"}, {"boundingBox": [431, 1226, 497, 1223, 498, 1255, 431, 1256], "text": "TBI.\""}]}, {"boundingBox": [202, 1291, 1126, 1289, 1127, 1322, 203, 1324], "text": "- go to this article from the Associated Press for more information", "words": [{"boundingBox": [203, 1292, 218, 1292, 220, 1324, 205, 1325], "text": "-"}, {"boundingBox": [224, 1292, 261, 1292, 263, 1324, 226, 1324], "text": "go"}, {"boundingBox": [267, 1292, 297, 1292, 299, 1324, 269, 1324], "text": "to"}, {"boundingBox": [304, 1292, 358, 1291, 360, 1323, 306, 1324], "text": "this"}, {"boundingBox": [364, 1291, 453, 1291, 454, 1323, 366, 1323], "text": "article"}, {"boundingBox": [459, 1291, 519, 1291, 521, 1322, 461, 1323], "text": "from"}, {"boundingBox": [535, 1291, 584, 1291, 585, 1322, 536, 1322], "text": "the"}, {"boundingBox": [591, 1291, 739, 1291, 740, 1321, 592, 1322], "text": "Associated"}, {"boundingBox": [746, 1291, 823, 1291, 824, 1321, 747, 1321], "text": "Press"}, {"boundingBox": [830, 1291, 871, 1291, 872, 1321, 831, 1321], "text": "for"}, {"boundingBox": [877, 1291, 953, 1291, 953, 1321, 878, 1321], "text": "more"}, {"boundingBox": [959, 1291, 1123, 1291, 1123, 1322, 960, 1321], "text": "information"}]}, {"boundingBox": [205, 1355, 1467, 1356, 1467, 1390, 204, 1389], "text": "ALSO: There was some good news for Pharmos, however. The company will be receiving a", "words": [{"boundingBox": [205, 1356, 300, 1357, 300, 1389, 205, 1388], "text": "ALSO:"}, {"boundingBox": [306, 1357, 388, 1357, 388, 1389, 306, 1389], "text": "There"}, {"boundingBox": [394, 1357, 451, 1358, 451, 1389, 394, 1389], "text": "was"}, {"boundingBox": [457, 1358, 535, 1358, 535, 1390, 457, 1389], "text": "some"}, {"boundingBox": [541, 1358, 613, 1358, 612, 1390, 541, 1390], "text": "good"}, {"boundingBox": [619, 1358, 695, 1358, 694, 1390, 619, 1390], "text": "news"}, {"boundingBox": [701, 1358, 741, 1358, 740, 1390, 701, 1390], "text": "for"}, {"boundingBox": [747, 1358, 881, 1358, 881, 1390, 747, 1390], "text": "Pharmos,"}, {"boundingBox": [888, 1358, 1024, 1358, 1024, 1390, 887, 1390], "text": "however."}, {"boundingBox": [1030, 1358, 1083, 1358, 1083, 1390, 1030, 1390], "text": "The"}, {"boundingBox": [1089, 1358, 1217, 1357, 1217, 1390, 1089, 1390], "text": "company"}, {"boundingBox": [1224, 1357, 1272, 1357, 1271, 1390, 1223, 1390], "text": "will"}, {"boundingBox": [1278, 1357, 1314, 1357, 1313, 1390, 1278, 1390], "text": "be"}, {"boundingBox": [1320, 1357, 1450, 1356, 1450, 1389, 1320, 1390], "text": "receiving"}, {"boundingBox": [1457, 1356, 1467, 1356, 1467, 1389, 1456, 1389], "text": "a"}]}, {"boundingBox": [202, 1389, 1428, 1390, 1427, 1422, 201, 1421], "text": "$10 million milestone payment from Bausch & Lomb for the eye treatment Zylet, Article", "words": [{"boundingBox": [204, 1391, 257, 1391, 257, 1421, 204, 1421], "text": "$10"}, {"boundingBox": [265, 1391, 358, 1391, 358, 1421, 265, 1421], "text": "million"}, {"boundingBox": [366, 1391, 504, 1392, 504, 1421, 366, 1421], "text": "milestone"}, {"boundingBox": [510, 1392, 636, 1392, 636, 1422, 510, 1421], "text": "payment"}, {"boundingBox": [642, 1392, 699, 1392, 699, 1422, 642, 1422], "text": "from"}, {"boundingBox": [717, 1392, 817, 1392, 818, 1422, 717, 1422], "text": "Bausch"}, {"boundingBox": [827, 1392, 847, 1392, 847, 1422, 827, 1422], "text": "&"}, {"boundingBox": [857, 1392, 936, 1392, 936, 1422, 857, 1422], "text": "Lomb"}, {"boundingBox": [942, 1392, 985, 1392, 985, 1422, 942, 1422], "text": "for"}, {"boundingBox": [991, 1392, 1038, 1392, 1039, 1422, 991, 1422], "text": "the"}, {"boundingBox": [1046, 1392, 1097, 1392, 1098, 1422, 1047, 1422], "text": "eye"}, {"boundingBox": [1103, 1392, 1247, 1391, 1248, 1423, 1104, 1422], "text": "treatment"}, {"boundingBox": [1253, 1391, 1336, 1391, 1337, 1423, 1254, 1423], "text": "Zylet,", "confidence": "Low"}, {"boundingBox": [1342, 1391, 1427, 1390, 1427, 1423, 1343, 1423], "text": "Article"}]}, {"boundingBox": [207, 1520, 1010, 1523, 1010, 1555, 206, 1552], "text": "5. Takeda suspends Phase III trial of diabetes drug", "words": [{"boundingBox": [207, 1522, 239, 1523, 239, 1553, 208, 1553], "text": "5."}, {"boundingBox": [245, 1523, 355, 1523, 356, 1553, 245, 1553], "text": "Takeda"}, {"boundingBox": [363, 1523, 512, 1524, 512, 1553, 364, 1553], "text": "suspends"}, {"boundingBox": [520, 1524, 615, 1524, 615, 1553, 520, 1553], "text": "Phase"}, {"boundingBox": [623, 1524, 670, 1524, 671, 1554, 623, 1553], "text": "III"}, {"boundingBox": [676, 1524, 744, 1524, 744, 1554, 677, 1554], "text": "trial"}, {"boundingBox": [750, 1524, 787, 1524, 787, 1554, 750, 1554], "text": "of"}, {"boundingBox": [793, 1524, 926, 1524, 926, 1555, 793, 1554], "text": "diabetes"}, {"boundingBox": [934, 1524, 1005, 1523, 1005, 1555, 934, 1555], "text": "drug"}]}, {"boundingBox": [196, 1586, 1422, 1585, 1423, 1620, 197, 1621], "text": "Japan's Takeda has stopped a Phase III trial of its experimental diabetes drug TAK-559", "words": [{"boundingBox": [203, 1588, 311, 1589, 312, 1620, 204, 1619], "text": "Japan's"}, {"boundingBox": [317, 1589, 418, 1590, 419, 1620, 318, 1620], "text": "Takeda"}, {"boundingBox": [424, 1590, 476, 1590, 477, 1620, 425, 1620], "text": "has"}, {"boundingBox": [482, 1590, 596, 1590, 598, 1621, 483, 1620], "text": "stopped"}, {"boundingBox": [604, 1590, 624, 1590, 626, 1621, 606, 1621], "text": "a"}, {"boundingBox": [630, 1590, 715, 1590, 716, 1621, 632, 1621], "text": "Phase"}, {"boundingBox": [721, 1590, 759, 1590, 760, 1621, 722, 1621], "text": "III"}, {"boundingBox": [765, 1590, 823, 1590, 824, 1621, 766, 1621], "text": "trial"}, {"boundingBox": [829, 1590, 859, 1590, 861, 1621, 830, 1621], "text": "of"}, {"boundingBox": [865, 1590, 903, 1590, 905, 1621, 867, 1621], "text": "its"}, {"boundingBox": [909, 1590, 1098, 1589, 1099, 1621, 911, 1621], "text": "experimental"}, {"boundingBox": [1104, 1589, 1222, 1588, 1224, 1620, 1105, 1621], "text": "diabetes"}, {"boundingBox": [1228, 1588, 1294, 1587, 1296, 1620, 1230, 1620], "text": "drug"}, {"boundingBox": [1302, 1587, 1421, 1586, 1423, 1619, 1304, 1620], "text": "TAK-559"}]}, {"boundingBox": [197, 1619, 1485, 1619, 1485, 1652, 198, 1653], "text": "after researchers received abnormal liver enzyme test results from patients taking the drug.", "words": [{"boundingBox": [203, 1621, 271, 1622, 270, 1653, 202, 1653], "text": "after"}, {"boundingBox": [277, 1622, 443, 1622, 442, 1653, 277, 1653], "text": "researchers"}, {"boundingBox": [449, 1622, 570, 1622, 570, 1653, 448, 1653], "text": "received"}, {"boundingBox": [577, 1622, 711, 1622, 710, 1653, 576, 1653], "text": "abnormal"}, {"boundingBox": [717, 1622, 781, 1622, 780, 1653, 716, 1653], "text": "liver"}, {"boundingBox": [787, 1622, 899, 1622, 898, 1653, 786, 1653], "text": "enzyme"}, {"boundingBox": [905, 1622, 960, 1621, 960, 1653, 904, 1653], "text": "test"}, {"boundingBox": [967, 1621, 1064, 1621, 1063, 1653, 966, 1653], "text": "results"}, {"boundingBox": [1070, 1621, 1130, 1621, 1129, 1653, 1069, 1653], "text": "from"}, {"boundingBox": [1144, 1621, 1260, 1620, 1259, 1653, 1143, 1653], "text": "patients"}, {"boundingBox": [1266, 1620, 1355, 1620, 1354, 1653, 1265, 1653], "text": "taking"}, {"boundingBox": [1361, 1619, 1410, 1619, 1410, 1653, 1360, 1653], "text": "the"}, {"boundingBox": [1418, 1619, 1484, 1619, 1484, 1653, 1418, 1653], "text": "drug."}]}, {"boundingBox": [203, 1651, 1457, 1652, 1456, 1685, 202, 1684], "text": "Elevated liver enzyme results have stopped the FDA from approving other diabetes drugs.", "words": [{"boundingBox": [203, 1653, 323, 1653, 324, 1685, 204, 1684], "text": "Elevated"}, {"boundingBox": [329, 1653, 394, 1653, 395, 1685, 330, 1685], "text": "liver"}, {"boundingBox": [400, 1653, 512, 1653, 513, 1685, 401, 1685], "text": "enzyme"}, {"boundingBox": [518, 1653, 614, 1653, 614, 1685, 519, 1685], "text": "results"}, {"boundingBox": [620, 1653, 691, 1653, 692, 1685, 620, 1685], "text": "have"}, {"boundingBox": [697, 1653, 811, 1653, 811, 1685, 698, 1685], "text": "stopped"}, {"boundingBox": [817, 1653, 866, 1653, 866, 1685, 817, 1685], "text": "the"}, {"boundingBox": [872, 1653, 931, 1653, 931, 1685, 872, 1685], "text": "FDA"}, {"boundingBox": [939, 1653, 998, 1653, 998, 1685, 939, 1685], "text": "from"}, {"boundingBox": [1014, 1653, 1154, 1652, 1155, 1685, 1014, 1685], "text": "approving"}, {"boundingBox": [1160, 1652, 1242, 1652, 1242, 1686, 1161, 1685], "text": "other"}, {"boundingBox": [1248, 1652, 1368, 1652, 1368, 1686, 1248, 1686], "text": "diabetes"}, {"boundingBox": [1374, 1652, 1455, 1652, 1455, 1686, 1374, 1686], "text": "drugs."}]}, {"boundingBox": [197, 1686, 1368, 1687, 1367, 1719, 196, 1718], "text": "TAK-559 was being developed as a successor to Takeda's Actos, which loses patent", "words": [{"boundingBox": [205, 1687, 325, 1688, 326, 1717, 207, 1716], "text": "TAK-559"}, {"boundingBox": [333, 1688, 389, 1688, 390, 1718, 334, 1718], "text": "was"}, {"boundingBox": [394, 1688, 473, 1689, 475, 1719, 396, 1718], "text": "being"}, {"boundingBox": [485, 1689, 628, 1689, 629, 1719, 486, 1719], "text": "developed"}, {"boundingBox": [634, 1689, 668, 1689, 670, 1719, 635, 1719], "text": "as"}, {"boundingBox": [674, 1689, 693, 1690, 695, 1720, 676, 1719], "text": "a"}, {"boundingBox": [701, 1690, 838, 1690, 840, 1720, 703, 1720], "text": "successor"}, {"boundingBox": [844, 1690, 875, 1689, 876, 1720, 846, 1720], "text": "to"}, {"boundingBox": [884, 1689, 1008, 1689, 1010, 1720, 886, 1720], "text": "Takeda's"}, {"boundingBox": [1014, 1689, 1102, 1689, 1104, 1719, 1015, 1720], "text": "Actos,"}, {"boundingBox": [1108, 1689, 1189, 1688, 1191, 1719, 1110, 1719], "text": "which"}, {"boundingBox": [1197, 1688, 1270, 1687, 1272, 1718, 1199, 1719], "text": "loses"}, {"boundingBox": [1276, 1687, 1365, 1687, 1367, 1718, 1278, 1718], "text": "patent"}]}, {"boundingBox": [203, 1720, 462, 1718, 463, 1748, 204, 1750], "text": "protection in 2010.", "words": [{"boundingBox": [204, 1722, 344, 1720, 345, 1749, 205, 1751], "text": "protection"}, {"boundingBox": [351, 1720, 379, 1720, 380, 1749, 352, 1749], "text": "in"}, {"boundingBox": [389, 1720, 464, 1719, 464, 1749, 389, 1749], "text": "2010."}]}, {"boundingBox": [198, 1783, 1019, 1784, 1018, 1817, 197, 1816], "text": "- see this article from the Financial Times for more details", "words": [{"boundingBox": [203, 1785, 219, 1785, 218, 1814, 201, 1814], "text": "-"}, {"boundingBox": [225, 1785, 275, 1786, 274, 1815, 224, 1814], "text": "see"}, {"boundingBox": [282, 1786, 338, 1786, 337, 1815, 281, 1815], "text": "this"}, {"boundingBox": [343, 1786, 430, 1786, 430, 1816, 342, 1815], "text": "article"}, {"boundingBox": [436, 1786, 493, 1787, 493, 1817, 435, 1816], "text": "from"}, {"boundingBox": [512, 1787, 560, 1787, 559, 1817, 511, 1817], "text": "the"}, {"boundingBox": [568, 1787, 697, 1786, 697, 1817, 567, 1817], "text": "Financial"}, {"boundingBox": [703, 1786, 784, 1786, 784, 1817, 702, 1817], "text": "Times"}, {"boundingBox": [790, 1786, 833, 1786, 832, 1817, 789, 1817], "text": "for"}, {"boundingBox": [838, 1786, 914, 1785, 914, 1817, 838, 1817], "text": "more"}, {"boundingBox": [925, 1785, 1018, 1784, 1018, 1816, 925, 1817], "text": "details"}]}, {"boundingBox": [206, 1914, 403, 1916, 403, 1947, 205, 1945], "text": "ALSO NOTED", "words": [{"boundingBox": [206, 1916, 281, 1916, 282, 1945, 207, 1945], "text": "ALSO"}, {"boundingBox": [294, 1916, 400, 1916, 399, 1947, 295, 1945], "text": "NOTED"}]}, {"boundingBox": [202, 1979, 1411, 1981, 1410, 2015, 201, 2013], "text": "TODAY'S SPOTLIGHT... Cardiome touts heart drug trial data Canada's Cardiome", "words": [{"boundingBox": [204, 1980, 341, 1980, 341, 2013, 205, 2013], "text": "TODAY'S"}, {"boundingBox": [347, 1980, 560, 1981, 561, 2014, 348, 2013], "text": "SPOTLIGHT..."}, {"boundingBox": [566, 1981, 718, 1982, 719, 2014, 567, 2014], "text": "Cardiome"}, {"boundingBox": [724, 1982, 805, 1982, 806, 2014, 725, 2014], "text": "touts"}, {"boundingBox": [811, 1982, 904, 1982, 905, 2015, 812, 2014], "text": "heart"}, {"boundingBox": [913, 1982, 980, 1982, 981, 2015, 914, 2015], "text": "drug"}, {"boundingBox": [987, 1982, 1060, 1982, 1062, 2015, 988, 2015], "text": "trial"}, {"boundingBox": [1067, 1982, 1132, 1982, 1133, 2015, 1068, 2015], "text": "data"}, {"boundingBox": [1138, 1982, 1266, 1982, 1268, 2014, 1140, 2015], "text": "Canada's"}, {"boundingBox": [1273, 1982, 1409, 1981, 1411, 2014, 1274, 2014], "text": "Cardiome"}]}, {"boundingBox": [206, 2014, 1444, 2015, 1444, 2049, 205, 2048], "text": "Pharma says that a Phase III trial of RSD1235 shows it was effective in restoring normal", "words": [{"boundingBox": [206, 2017, 312, 2016, 312, 2049, 206, 2048], "text": "Pharma"}, {"boundingBox": [318, 2016, 383, 2016, 382, 2049, 318, 2049], "text": "says"}, {"boundingBox": [389, 2016, 449, 2016, 449, 2049, 388, 2049], "text": "that"}, {"boundingBox": [455, 2016, 474, 2016, 473, 2049, 455, 2049], "text": "a"}, {"boundingBox": [480, 2016, 567, 2016, 567, 2049, 480, 2049], "text": "Phase"}, {"boundingBox": [573, 2016, 610, 2016, 610, 2050, 573, 2049], "text": "III"}, {"boundingBox": [617, 2016, 677, 2015, 677, 2050, 617, 2050], "text": "trial"}, {"boundingBox": [683, 2015, 712, 2015, 712, 2050, 683, 2050], "text": "of"}, {"boundingBox": [718, 2015, 851, 2015, 851, 2050, 718, 2050], "text": "RSD1235"}, {"boundingBox": [857, 2015, 946, 2015, 946, 2050, 857, 2050], "text": "shows"}, {"boundingBox": [952, 2015, 975, 2015, 975, 2050, 953, 2050], "text": "it"}, {"boundingBox": [981, 2015, 1039, 2015, 1040, 2050, 982, 2050], "text": "was"}, {"boundingBox": [1045, 2015, 1164, 2015, 1164, 2050, 1046, 2050], "text": "effective"}, {"boundingBox": [1170, 2015, 1199, 2015, 1200, 2050, 1170, 2050], "text": "in"}, {"boundingBox": [1205, 2015, 1333, 2016, 1334, 2050, 1206, 2050], "text": "restoring"}, {"boundingBox": [1340, 2016, 1441, 2016, 1442, 2050, 1341, 2050], "text": "normal"}]}, {"boundingBox": [198, 2047, 1431, 2047, 1431, 2081, 199, 2082], "text": "heart rhythm to 52 percent of patients suffering atrial fibrillation compared to 4 percent", "words": [{"boundingBox": [201, 2049, 279, 2049, 279, 2080, 201, 2079], "text": "heart"}, {"boundingBox": [285, 2050, 379, 2050, 379, 2081, 285, 2080], "text": "rhythm", "confidence": "Low"}, {"boundingBox": [395, 2050, 426, 2050, 426, 2081, 395, 2081], "text": "to"}, {"boundingBox": [436, 2050, 471, 2050, 471, 2081, 436, 2081], "text": "52"}, {"boundingBox": [479, 2050, 587, 2050, 587, 2082, 479, 2081], "text": "percent"}, {"boundingBox": [593, 2050, 626, 2050, 626, 2082, 593, 2082], "text": "of"}, {"boundingBox": [632, 2050, 746, 2050, 746, 2082, 632, 2082], "text": "patients"}, {"boundingBox": [751, 2050, 875, 2050, 875, 2082, 751, 2082], "text": "suffering", "confidence": "Low"}, {"boundingBox": [885, 2050, 959, 2050, 959, 2082, 885, 2082], "text": "atrial"}, {"boundingBox": [965, 2050, 1106, 2049, 1106, 2082, 965, 2082], "text": "fibrillation", "confidence": "Low"}, {"boundingBox": [1112, 2049, 1253, 2049, 1253, 2081, 1112, 2082], "text": "compared", "confidence": "Low"}, {"boundingBox": [1259, 2049, 1290, 2048, 1290, 2081, 1259, 2081], "text": "to"}, {"boundingBox": [1298, 2048, 1318, 2048, 1318, 2081, 1298, 2081], "text": "4"}, {"boundingBox": [1325, 2048, 1431, 2047, 1432, 2080, 1326, 2081], "text": "percent", "confidence": "Low"}]}, {"boundingBox": [1404, 2152, 1651, 2149, 1652, 2178, 1404, 2180], "text": "PLA-TAK-00020531", "words": [{"boundingBox": [1408, 2152, 1653, 2150, 1653, 2177, 1409, 2180], "text": "PLA-TAK-00020531"}]}, {"boundingBox": [384, 2193, 1317, 2192, 1318, 2231, 385, 2232], "text": "Source: https://www.indup50 80boosts.ucsf.edu/docs/ptjf0226", "words": [{"boundingBox": [387, 2195, 502, 2196, 503, 2231, 388, 2230], "text": "Source:"}, {"boundingBox": [509, 2196, 814, 2197, 815, 2233, 510, 2231], "text": "https://www.indup50", "confidence": "Low"}, {"boundingBox": [830, 2197, 1315, 2193, 1316, 2230, 831, 2233], "text": "80boosts.ucsf.edu/docs/ptjf0226", "confidence": "Low"}]}]}]}